Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 295

1.

Novel Therapies in Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Kidney Int Rep. 2017 Nov 28;3(3):530-541. doi: 10.1016/j.ekir.2017.11.017. eCollection 2018 May. Review.

2.

Management of the elderly patient with AL amyloidosis.

Nuvolone M, Milani P, Palladini G, Merlini G.

Eur J Intern Med. 2018 May 22. pii: S0953-6205(18)30181-X. doi: 10.1016/j.ejim.2018.05.004. [Epub ahead of print]

PMID:
29801808
3.

Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Mediterr J Hematol Infect Dis. 2018 Mar 1;10(1):e2018022. doi: 10.4084/MJHID.2018.022. eCollection 2018. Review.

4.

The elusive pathogenesis of Schnitzler syndrome.

Palladini G, Merlini G.

Blood. 2018 Mar 1;131(9):944-946. doi: 10.1182/blood-2018-01-824862. No abstract available.

PMID:
29496698
5.

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.

Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G.

Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31.

PMID:
29386197
6.

New concepts in the treatment and diagnosis of amyloidosis.

Milani P, Palladini G, Merlini G.

Expert Rev Hematol. 2018 Feb;11(2):117-127. doi: 10.1080/17474086.2018.1424534. Epub 2018 Jan 10.

PMID:
29307226
7.

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.

Oberti L, Rognoni P, Barbiroli A, Lavatelli F, Russo R, Maritan M, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Sci Rep. 2017 Dec 1;7(1):16809. doi: 10.1038/s41598-017-16953-7.

8.

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.

Imperlini E, Gnecchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M, Malpasso G, Valentini V, Palladini G, Orrù S, Ferraro G, Milani P, Perlini S, Salvatore F, Merlini G, Lavatelli F.

Sci Rep. 2017 Nov 15;7(1):15661. doi: 10.1038/s41598-017-15424-3.

9.

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2018 Feb 1;131(5):525-532. doi: 10.1182/blood-2017-04-780544. Epub 2017 Nov 3.

PMID:
29101236
10.

The lung in amyloidosis.

Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170046. doi: 10.1183/16000617.0046-2017. Print 2017 Sep 30. Review.

11.

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Meziane I, Huhn S, Filho MIDS, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K.

Haematologica. 2017 Oct;102(10):e411-e414. doi: 10.3324/haematol.2017.171108. Epub 2017 Jul 4. No abstract available.

12.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

PMID:
28550039
13.

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G.

Blood. 2017 Aug 3;130(5):625-631. doi: 10.1182/blood-2017-02-767467. Epub 2017 May 25.

PMID:
28546143
14.

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Lavatelli F, Nuvolone M, Ferraro G, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):64-65. doi: 10.1080/13506129.2017.1293517. No abstract available.

PMID:
28434343
15.

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis.

Basset M, Milani P, Russo F, Lavatelli F, Nuvolone M, Foli A, Perlini S, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):60-61. doi: 10.1080/13506129.2017.1292901. No abstract available.

PMID:
28434342
16.

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Merlini G.

Amyloid. 2017 Mar;24(sup1):68-69. doi: 10.1080/13506129.2017.1293644. No abstract available.

PMID:
28434326
17.

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

Russo F, Valentini V, Basset M, Bosoni T, Milani P, Ferraro G, Pirolini L, Foli A, Lavatelli F, Belvisi F, Consogno G, Nuvolone M, Li Bergolis F, Bozzola M, Albertini R, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):66-67. doi: 10.1080/13506129.2017.1293643. No abstract available.

PMID:
28434323
18.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240. No abstract available.

PMID:
28434298
19.

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Perlini S, Merlini G.

Amyloid. 2017 Mar;24(sup1):54-55. doi: 10.1080/13506129.2017.1289916. No abstract available.

PMID:
28434293
20.

Prognostication of survival and progression to dialysis in AA amyloidosis.

Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, Lavatelli F, Nuvolone M, Casarini S, Obici L, Merlini G.

Amyloid. 2017 Mar;24(sup1):136-137. doi: 10.1080/13506129.2017.1289917. No abstract available.

PMID:
28434292
21.

Regulated expression of amyloidogenic immunoglobulin light chains in mice.

Nuvolone M, Sorce S, Pelczar P, Rushing E, Lavatelli F, Rognoni P, Valentini V, Palladini G, Merlini G, Aguzzi A.

Amyloid. 2017 Mar;24(sup1):52-53. doi: 10.1080/13506129.2017.1289914. No abstract available.

PMID:
28434289
22.

Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.

Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, Lavatelli F, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, Nuvolone M, Albertini R, Cogne M, Merlini G.

Clin Chem Lab Med. 2017 Oct 26;55(11):1734-1743. doi: 10.1515/cclm-2016-1024.

PMID:
28343171
23.

Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.

Diomede L, Romeo M, Rognoni P, Beeg M, Foray C, Ghibaudi E, Palladini G, Cherny RA, Verga L, Capello GL, Perfetti V, Fiordaliso F, Merlini G, Salmona M.

Antioxid Redox Signal. 2017 Sep 20;27(9):567-582. doi: 10.1089/ars.2016.6848. Epub 2017 Mar 3.

PMID:
28132512
24.

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.

Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E, Palladini G, Milani P, Cerruti F, Cascio P, Casarini S, Rognoni P, Touvier T, Marcatti M, Ciceri F, Mangiacavalli S, Corso A, Merlini G, Cenci S.

Blood. 2017 Apr 13;129(15):2132-2142. doi: 10.1182/blood-2016-08-730978. Epub 2017 Jan 27.

25.

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2017 Apr 13;129(15):2120-2123. doi: 10.1182/blood-2016-12-756528. Epub 2017 Jan 27.

26.

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Morgan GJ, Houlston R, Goldschmidt H, Jauch A, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Hemminki K.

Leukemia. 2017 Aug;31(8):1735-1742. doi: 10.1038/leu.2016.387. Epub 2016 Dec 27.

PMID:
28025584
27.

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, Dimopoulos MA.

Blood. 2017 Jan 26;129(4):456-459. doi: 10.1182/blood-2016-09-742411. Epub 2016 Nov 21.

28.

N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.

Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A.

Am J Hematol. 2016 Nov;91(11):1129-1134. doi: 10.1002/ajh.24532. Epub 2016 Aug 29.

29.

Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.

Milani P, Palladini G, Merlini G.

Scand J Clin Lab Invest Suppl. 2016;245:S113-8. doi: 10.1080/00365513.2016.1210337. Epub 2016 Jul 28. Review.

PMID:
27467897
30.

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL.

Leukemia. 2016 Oct;30(10):1979-1986. doi: 10.1038/leu.2016.191. Epub 2016 Jul 15. Review.

31.

In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.

Ami D, Lavatelli F, Rognoni P, Palladini G, Raimondi S, Giorgetti S, Monti L, Doglia SM, Natalello A, Merlini G.

Sci Rep. 2016 Jul 4;6:29096. doi: 10.1038/srep29096.

32.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN.

Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.

33.

European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.

Sachchithanantham S, Roussel M, Palladini G, Klersy C, Mahmood S, Venner CP, Gibbs S, Gillmore J, Lachmann H, Hawkins PN, Jaccard A, Merlini G, Wechalekar AD.

J Clin Oncol. 2016 Jun 10;34(17):2037-45. doi: 10.1200/JCO.2015.63.3123. Epub 2016 Apr 25.

PMID:
27114592
34.

What is new in diagnosis and management of light chain amyloidosis?

Palladini G, Merlini G.

Blood. 2016 Jul 14;128(2):159-68. doi: 10.1182/blood-2016-01-629790. Epub 2016 Apr 6. Review.

35.

Effects of a Bioavailable Arabinoxylan-enriched White Bread Flour on Postprandial Glucose Response in Normoglycemic Subjects.

Giulia Falchi A, Grecchi I, Muggia C, Palladini G, Perlini S.

J Diet Suppl. 2016 Nov;13(6):626-33. doi: 10.3109/19390211.2016.1156798. Epub 2016 Apr 6.

PMID:
27049812
36.

The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis.

Palladini G, Milani P, Foli A, Basset M, Russo F, Bosoni T, Pirolini L, Valentini V, Ferraro G, Lavatelli F, Barassi A, Albertini R, Merlini G.

Clin Chem Lab Med. 2016 Jun 1;54(6):939-45. doi: 10.1515/cclm-2015-0985.

PMID:
26943606
37.

Systemic amyloidoses and proteomics: The state of the art.

Lavatelli F, di Fonzo A, Palladini G, Merlini G.

EuPA Open Proteom. 2016 Feb 23;11:4-10. doi: 10.1016/j.euprot.2016.02.003. eCollection 2016 Jun.

38.

Enlightening light chain deposition disease.

Merlini G, Palladini G.

Blood. 2015 Dec 24;126(26):2770-1. doi: 10.1182/blood-2015-10-672626. No abstract available.

39.

A patient with AL amyloidosis with negative free light chain results.

Milani P, Valentini V, Ferraro G, Basset M, Russo F, Foli A, Palladini G, Merlini G.

Clin Chem Lab Med. 2016 Jun 1;54(6):1035-7. doi: 10.1515/cclm-2015-0847.

PMID:
26677890
40.

Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury: A review.

Palladini G, Ferrigno A, Richelmi P, Perlini S, Vairetti M.

World J Gastroenterol. 2015 Nov 14;21(42):12114-24. doi: 10.3748/wjg.v21.i42.12114. Review.

41.

Novel strategies for the diagnosis and treatment of cardiac amyloidosis.

Palladini G, Milani P, Merlini G.

Expert Rev Cardiovasc Ther. 2015 Nov;13(11):1195-211. doi: 10.1586/14779072.2015.1093936. Epub 2015 Oct 23. Review.

PMID:
26496239
42.

Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis.

Caccialanza R, Palladini G, Cereda E, Bonardi C, Milani P, Cameletti B, Quarleri L, Cappello S, Foli A, Lavatelli F, Klersy C, Merlini G.

Nutrition. 2015 Oct;31(10):1228-34. doi: 10.1016/j.nut.2015.04.011. Epub 2015 May 11.

PMID:
26250487
43.

Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.

Lavatelli F, Imperlini E, Orrù S, Rognoni P, Sarnataro D, Palladini G, Malpasso G, Soriano ME, Di Fonzo A, Valentini V, Gnecchi M, Perlini S, Salvatore F, Merlini G.

FASEB J. 2015 Nov;29(11):4614-28. doi: 10.1096/fj.15-272179. Epub 2015 Jul 28.

PMID:
26220173
44.

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.

Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD.

Blood. 2015 Jul 30;126(5):612-5. doi: 10.1182/blood-2015-01-620302. Epub 2015 May 18.

45.

A practical approach to the diagnosis of systemic amyloidoses.

Fernández de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, Obici L, Milani P, Capello GL, Paulli M, Palladini G, Merlini G.

Blood. 2015 Apr 2;125(14):2239-44. doi: 10.1182/blood-2014-11-609883. Epub 2015 Jan 30.

46.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.

Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8.

47.

Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.

Merlini G, Palladini G.

Haematologica. 2014 Sep;99(9):1407-9. doi: 10.3324/haematol.2014.113464. No abstract available.

48.

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, Albertini R, Moratti R, Merlini G, Schönland S.

Blood. 2014 Oct 9;124(15):2325-32. doi: 10.1182/blood-2014-04-570010. Epub 2014 Aug 12.

49.

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, Nuvolone M, Obici L, Perlini S, Merlini G.

Leukemia. 2014 Dec;28(12):2311-6. doi: 10.1038/leu.2014.227. Epub 2014 Jul 25.

PMID:
25059496
50.

Lobe-specific heterogeneity in asymmetric dimethylarginine and matrix metalloproteinase levels in a rat model of obstructive cholestasis.

Ferrigno A, Palladini G, Bianchi A, Rizzo V, Di Pasqua LG, Perlini S, Richelmi P, Vairetti M.

Biomed Res Int. 2014;2014:327537. doi: 10.1155/2014/327537. Epub 2014 Jun 12.

Supplemental Content

Loading ...
Support Center